Original Research Article (Pfizer): First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7 (PTK7), in Advanced Solid Tumors

Original Research Article (Pfizer): First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7 (PTK7), in Advanced Solid Tumors

In the downloadable original research article sponsored by Pfizer, the digital tissue analysis was performed using the Flagship Biosciences proprietary Image Analysis platform. The article was published in the Journal: Clinical Cancer Research online first on June 3,...

Tissue Based Companion Diagnostics in a Regulated Space

Overview During a recent panel discussion, members of the Flagship Biosciences team and representatives from The Johns Hopkins University, Leap Therapeutics, and Corritori Consulting shared their thoughts on companion diagnostics development, with an emphasis on...

Flagship Spotlight: Roberto Gianani, MD

Introduction and Background Dr. Roberto Gianani, Chief Medical Officer at Flagship Biosciences, Inc., is a practicing pathologist who is board certified in anatomic pathology, clinical pathology, and pediatric pathology. He is fellowship-trained in surgical pathology...
SITC 2021

SITC 2021

SITC 2021 Annual Meeting: Flagship plans to present a poster at the Society for Immunotherapy of Cancer (SITC) 36th Anniversary Annual Meeting, which is taking place both virtually and in person November 10-14, 2021 at the Walter E. Washington Convention Center in...